Better assessment of the tumor microenvironment is key to predicting treatment response and potential resistance to therapy.
Revolutionizing the Treatment of Cancer is Our Goal
ClearLight is developing CLARITY, a next generation tissue processing and imaging technology that will deliver an unprecedented way to visualize and quantify three-dimensional (3D) relationships within the microenvironment of diseased tissues. The technology provides a suite of powerful tools which will enable the measurement of important spatial relationships between different cell types, vasculature and nucleic acids within the tumor and surrounding tissue enabling better treatment decisions for patients.
Tissue-based characterization continues to serve as one of the gold standards for the diagnosis and treatment of cancer and other diseases. Obtaining high-resolution, three-dimensional information from solid tumors or other diseased tissue, while maintaining the global perspective needed to understand the complex tissue microenvironment, represents a key challenge for preclinical and clinical disease applications.
Immuno-oncology drugs continue to have response rates in the 10 – 30% range. The range of drug options, including combination therapy, is growing at an accelerated pace creating the need for more effective prognostic and predictive biomarkers. Assessing biomarkers of interest via multiplex immunofluorescence is an effective and efficient advance in cancer tissue analysis. CLARITY, with deep 3-D imaging, will identify specific immune cell phenotypes, assess spatial locations in the tumor microenvironment and assess immune check-point expression simultaneously on one sample.
Imagine immunofluorescence multiplexing on 3D tissue volumes